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Background: Misoprostol is an effective medical method for the management of pregnancy 
loss. However, data on its efficacy and safety in women with previous cesarean deliveries 
are limited.
Case presentation: We report a 36-year-old patient, gravida 11 para 6, with a diagnosis of 
missed miscarriage at 15 weeks of gestation. The patient had a significant obstetric history of 
previous five cesarean deliveries and uterine rupture. Following patient counseling about the 
medical and surgical options of managing her miscarriage, the patient opted for medical method. 
Low-dose misoprostol of 100 µg was inserted vaginally and repeated again after 6 hours. The 
patient had an uneventful complete miscarriage following the second dose of misoprostol. 
No uterine rupture, no extra vaginal bleeding, and no blood transfusion were observed.
Conclusion: We conclude that adopting a low-dose misoprostol protocol could be potentially 
safe and effective in managing second trimester missed miscarriage in women with repeated 
cesarean deliveries and/or uterine rupture history. Further studies are needed to confirm 
these results.
Keywords: cesarean section, uterine rupture, prostaglandin E1, misoprostol, second trimester, 
miscarriage, abortion
Introduction
Uterine rupture is one of the most catastrophic obstetric events that is associated with 
a high incidence of morbidity and mortality. Complications of uterine rupture can 
affect not only the current pregnancy but also future fertility and future pregnancy 
outcomes. Uterine rupture is more common in grand multiparous women and in those 
with previous cesarean sections.1,2
The rate of cesarean section is increasing worldwide. Consequently, the rate of 
women with a previous cesarean section is increasing and the risk of uterine rupture 
is becoming higher. Although the incidence rate of uterine rupture in women with 
previously scarred uterus remains low (,1%), it is still considered as a threat for 
obstetricians.2
Misoprostol, a prostaglandin E1 (PGE1) analog, is widely used for the medical 
management of pregnancy loss. Misoprostol is inexpensive and stable at room tempera-
ture and can be given orally, vaginally, sublingually, buccally, or rectally. However, 
its use for managing miscarriage cases is still off-label.3
Different protocols are available for the medical management of first and second 
trimester miscarriages using misoprostol.2,4,5 However, a definite misoprostol protocol 
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with good efficacy and safety for termination of pregnancy 
in women with more than one previous cesarean delivery is 
lacking.6,7 This case report presents our experience with the 
use of misoprostol for the management of second trimester 
miscarriage in a high-risk patient with previous five cesarean 
sections and uterine rupture.
Case presentation
A 36-year-old patient, gravida 11 para 6, with an ultrasound 
diagnosis of “missed miscarriage”, presented to our hospital 
with lower abdominal pain. She was 18+ gestational weeks 
by the last menstrual period (LMP) and 15+ gestational 
weeks by the ultrasound. Her previous obstetric history was 
significant for five lower segment cesarean sections (LSCS), 
four miscarriages, and one uterine rupture.
In her fifth pregnancy, she had a fetal demise at ~24 weeks 
of gestation, which was medically terminated. The patient 
was induced once; however, details of the medical induction 
were not available to review. The pregnancy termination 
was complicated by uterine rupture, which was managed by 
laparotomy, hysterotomy, and uterine rupture repair. Two 
of the five LSCS were done electively following the uterine 
rupture repair. The patient was healthy otherwise.
On physical examination, the patient was vitally stable, 
and the abdomen was soft with no tenderness on palpation. 
Pelvic transabdominal ultrasound was requested to rule out 
scar rupture. The myometrium–bladder interface was pre-
served, and scar thickness was 5 mm, which was normal for 
a previous cesarean section.8,9 All laboratory findings were 
within the normal ranges.
Conservative, medical, and surgical management options 
and the associated risks and benefits were discussed with the 
patient. She opted for medical management. Accordingly, 
a low-dose misoprostol of 100 µg was inserted vaginally 
in the posterior fornix, and 6 hours later, a repeat dose was 
given. Two hours after the second dose, the patient started 
to have pain and contractions. She was vitally stable. Her 
vaginal examination revealed an opened cervical os, and 
tissues were felt in the vagina; hence, the patient was shifted 
to labor and delivery suite for monitoring. After receiving 
adequate analgesia, a pelvic transabdominal ultrasound was 
done for scar thickness, which showed a thinning out of 
the myometrium at a scar site measuring 2 mm. Two hours 
later, the fetus was aborted that weighed 60 g, and 20 units 
of oxytocin infusion was started. One hour later, the placenta 
was delivered completely. The estimated blood loss was 
180 mL. The patient was vitally stable all through with no 
extra bleeding.
The following day, the patient was stable with minimal 
vaginal bleeding and the repeated complete blood count 
(CBC) was normal; a prophylactic antibiotic amoxicillin– 
clavulanate 625 mg every 8 hours orally for 7 days was 
started. On Day 2 post miscarriage, the patient was discharged 
home with a follow-up appointment.
Discussion
To our knowledge, there are no published reports describ-
ing the outcomes of low-dose misoprostol in managing 
the second trimester missed miscarriage in women with 
previous five cesarean deliveries and a history of uterine 
rupture. Different protocols are available for the medical 
management of second trimester miscarriage in women with 
intact uterus.4,5 However, management options for cases with 
scarred uterus are limited and the potential risk for maternal 
complications is high.6,7 Hence, it is essential to report out-
comes of management.
The optimal dose of misoprostol varies widely from 20 
to 600 µg depending on the indication and the gestational age. 
In women with a scarred uterus, lower doses of misoprostol 
are recommended due to the risk of uterine rupture.5 In this 
case report, a low-dose misoprostol of 100 µg every 6 hours 
was considered to minimize the risk of uterine rupture while 
maintaining effectiveness.
Two systematic reviews published in 2009 evaluated 
the risk of uterine rupture in women with previous cesarean 
delivery who used misoprostol for the management of 
second trimester abortion.10,11 The risk of uterine rupture 
for women with or without previous cesarean delivery was 
similar. Nevertheless, there was insufficient information 
about uterine rupture risk in women with more than one 
previous cesarean delivery or with previous classical cesarean 
section, and information about optimum dosing regimen of 
misoprostol was missing. Accordingly, findings should be 
applied with caution.
A more recent systematic review and meta-analysis 
assessed the efficacy and safety of cervical ripening agents 
in the second trimester of pregnancy in patients with a 
previous cesarean delivery.12 The review concluded that 
PGE1 use was efficacious and was not associated with a 
significantly increased risk for uterine rupture among women 
with only one cesarean delivery. However, in women with 
two or more cesarean deliveries, the risk for uterine rupture 
increased significantly compared to that in women without 
a previous cesarean delivery, although the absolute risk 
appeared to be relatively small. The review results were 
limited by the variation in hospital protocols, doses, routes 
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of administration, and nonuniform reporting of the number 
of previous cesarean deliveries (1 or .1), as well as the 
lack of information regarding the types of previous uterine 
scar. The use of misoprostol in two women with previous 
three cesarean deliveries was described by Alsibiani.13 One 
woman received 800 µg of oral misoprostol for the second 
trimester termination of pregnancy, while the other woman 
received 800 µg of vaginal misoprostol for the first trimester 
missed miscarriage. Favorable results were reported concern-
ing a single high dose of misoprostol use as part of abortion 
management, but the safety could not be ascertained from 
that study.
Overall, limited data are available regarding misoprostol 
safety in women with previous multiple cesarean deliver-
ies, and available evidences are mainly dependent on indi-
vidual practice and/or underpowered retrospective studies. 
Furthermore, there are inconsistencies about the optimum 
regimen of misoprostol, and the optimum dose is yet to 
be established.
Conclusion
Favorable results were obtained with low-dose misoprostol 
for the second trimester missed miscarriage management in 
a woman with previous repeated cesarean deliveries and a 
history of uterine rupture. Safety concerns such as uterine 
rupture and excessive bleeding were not encountered. 
However, the effectiveness and safety cannot be ascertained 
based on this case report solely.
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